HLA-E and neoplasm: NK cells are under constitutive inhibition by inhibitory receptors for MHC class I, and genome-scale CRISPR-based gene editing screens have revealed that HLA-E interactions with NKG2A are a key determinant for tumour cell sensitivity to NK-cell mediated lysis [106].